Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19

nork Trojaniello, C., Vitale, M.G., Ascierto, P.A.
Argitaratua izan da Ann Oncol (2021)

How we treat locoregional melanoma

nork Troiani, T., De Falco, V., Napolitano, S., Trojaniello, C., Ascierto, P.A.
Argitaratua izan da ESMO Open (2021)

Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

nork Pisano, M., Baldinu, P., Sini, M. C., Ascierto, P. A., Tanda, F., Palmieri, G.
Argitaratua 2008

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases

nork Palmieri, G, Cossu, A, Ascierto, P A, Botti, G, Strazzullo, M, Lissia, A, Colombino, M, Casula, M, Floris, C, Tanda, F, Pirastu, M, Castello, G
Argitaratua 2000

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

nork Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G., Rau, T., Botti, G., Marincola, F. M., Ciliberto, G., Pages, F., Ascierto, P. A., Capone, M.
Argitaratua izan da J Transl Med (2016)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

nork De Divitiis, C., von Arx, C., Grimaldi, A. M., Cicala, D., Tatangelo, F., Arcella, A., Romano, G. M., Simeone, E., Iaffaioli, R. V., Ascierto, P. A., Tafuto, S.
Argitaratua izan da J Transl Med (2016)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

nork Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Argitaratua izan da Ann Oncol (2016)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

nork Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M
Argitaratua 2014

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

nork Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Argitaratua izan da Ann Oncol (2017)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

nork Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Argitaratua izan da Ann Oncol (2016)

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

nork Marabelle, A, Andtbacka, R, Harrington, K, Melero, I, Leidner, R, de Baere, T, Robert, C, Ascierto, P A, Baurain, J -F, Imperiale, M, Rahimian, S, Tersago, D, Klumper, E, Hendriks, M, Kumar, R, Stern, M, Öhrling, K, Massacesi, C, Tchakov, I, Tse, A, Douillard, J -Y, Tabernero, J, Haanen, J, Brody, J
Argitaratua izan da Ann Oncol (2018)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

nork Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Argitaratua izan da ESMO Open (2016)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

nork Eggermont, A.M.M., Chiario-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J.D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P.A., Richards, J.M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J.S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J.C., Hodi, F.S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S., Testori, A.
Argitaratua izan da N Engl J Med (2016)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

nork Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S., Larkin, J.
Argitaratua izan da N Engl J Med (2017)